Overview

Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography

Status:
Not yet recruiting

Trial end date:
2023-04-01

Target enrollment:

Participant gender:

Summary

Randomized parallel group study comparing the renal safety of Captisol-Enabled™ Iohexol (CE-Iohexol) Injection and Omnipaque™ (Iohexol) Injection in patients with impaired renal function undergoing coronary angiography.

Phase:

Phase 2

Details

Lead Sponsor:

Ligand Pharmaceuticals

Collaborator:

CyDex Pharmaceuticals, Inc.